In the UKB, genetically predicted β2M showed a positive association with diffuse large B-cell lymphoma (DLBCL; odds ratio [OR]: 1.742 per standard deviation increase in β2M; 95% confidence interval [CI]: 1.215–2.498; P = 3.00 × 10−3; FDR = 7.50× 10−3) and Hodgkin lymphoma (HL; OR: 2.270; 95% CI: 1.525–3.380; P = 5.15 × 10−5; FDR =2.58 × 10−4). This evidence concerns the gene B2M and Hodgkins lymphoma.